Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Arcturus Therapeutics Ltd. (NASDAQ: ARCT).

Full DD Report for ARCT

You must become a subscriber to view this report.


Recent News from (NASDAQ: ARCT)

Arcturus Therapeutics Files Form 20-F
SAN DIEGO, May 14, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced the filing of the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2017 with the U.S. Securities and Exchange Commission o...
Source: GlobeNewswire
Date: May, 14 2018 17:33
Arcturus Therapeutics Founder Joseph Payne Welcomes Court Decision to Set Date and Agenda of Extraordinary General Meeting to Vote for New Board Members
Court rules that a notification for Extraordinary General Meeting must be issued this week The Extraordinary General Meeting to be scheduled between June 18 and June 24, 2018 Court ruling also establishes an agenda for the June meeting that is substantially identical to the agen...
Source: GlobeNewswire
Date: May, 14 2018 15:05
Cirius Therapeutics completes enrollment in mid-stage study of lead candidate in NASH
Privately held Cirius Therapeutics announces that it has reached the enrollment target in a Phase 2b clinical trial, EMMINENCE , assessing lead candidate MSDC-0602K in patients with NASH and liver fibrosis. More news on: Conatus Pharmaceuticals, Galectin Therapeutics, Inc., Navidea Bi...
Source: SeekingAlpha
Date: May, 02 2018 10:47
Arcturus Therapeutics Founder Joseph Payne Successfully Prevents Board's Egregious Attempt to Dilute Shareholders
Israeli District Court enjoins attempt by board to dilute shareholders through sale of 24.9% of Arcturus share capital Court found sufficient evidence to support the claim that the members of the Arcturus board are motivated by their own self-interests instead of the interests of Arc...
Source: GlobeNewswire
Date: May, 02 2018 09:30
Blog Exposure - Arcturus Initiates Lawsuit against Former CEO Joseph Payne for Misconduct and Violations of Federal Disclosure
Stock Monitor: PLx Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 24, 2018 / Active-Investors.com has just released a free research report on Arcturus Therapeutics Ltd (NASDAQ: ARCT ) ("Arcturus"). If you want access to this report all you need to do is sign up now by...
Source: ACCESSWIRE IA
Date: April, 24 2018 07:50
Arcturus Therapeutics Founder Joseph Payne Dismisses Board's Baseless Lawsuit as Desperate Entrenchment Tactic
Warns lawsuit is another attempt by Arcturus’ board to distract shareholders from the Company’s abhorrent governance deficiencies Calls on board to respect the rights of all shareholders and immediately set date for Extraordinary General Meeting SAN DIEGO, April 23, 2...
Source: GlobeNewswire
Date: April, 23 2018 09:30
Arcturus Therapeutics Files Lawsuit Against Joseph E. Payne and His Associates for Violations of Federal Securities Laws
Complaint Details Multiple Violations of Federal Securities Laws by Undisclosed Group Led by Payne SAN DIEGO, April 20, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, initiated a lawsuit in the United States District Court f...
Source: GlobeNewswire
Date: April, 20 2018 08:00
Arcturus Therapeutics Founder Joseph Payne Disappointed by Board's Desperate Attempt to Delay Meeting and Avoid Shareholder Accountability
Change in Arcturus board is needed on an urgent basis to improve the company’s performance Board’s decision to indefinitely delay inevitable change is a clear act of entrenchment Overwhelming support for Mr. Payne’s nominees indicates change is mandated, positi...
Source: GlobeNewswire
Date: April, 13 2018 11:43
Arcturus Therapeutics Issues Statement Regarding Timing of Extraordinary General Meeting of Shareholders
Postponement due to Joseph Payne’s Focus on Advancing His Personal Agenda at the Expense of Arcturus Shareholders SAN DIEGO, April 08, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced that upon the recommendati...
Source: GlobeNewswire
Date: April, 08 2018 10:08
RNAi For Hepatitis B - A False Hope For A Cure?
Editor's note: Seeking Alpha is proud to welcome BZ Equity Research as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Hepat...
Source: SeekingAlpha
Date: April, 06 2018 14:59

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-185.936.176.355.9220,892
2018-05-175.936.176.355.9220,892

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-181,1922,22553.5730Short
2018-05-172,2054,68047.1154Short
2018-05-1610,56413,78276.6507Short
2018-05-156,83713,92749.0917Short
2018-05-142,1345,43139.2929Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ARCT.


About Arcturus Therapeutics Ltd. (NASDAQ: ARCT)

Logo for Arcturus Therapeutics Ltd. (NASDAQ: ARCT)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $22,403,493 - 05/11/2018
    • Issue and Outstanding: 3,937,345 - 11/16/2017

     


    Recent Filings from (NASDAQ: ARCT)

    Amendment to a SC 13D filing
    Filing Type: SC 13D/AFiling Source: edgar
    Filing Date: May, 15 2018
    Annual and transition report of foreign private issuers under sections 13 or 15(d)
    Filing Type: 20-FFiling Source: edgar
    Filing Date: May, 14 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 14 2018
    Amendment to a SC 13D filing
    Filing Type: SC 13D/AFiling Source: edgar
    Filing Date: May, 02 2018
    Filing by person(s) reporting owned shares of common stock in a public company >5%
    Filing Type: SC 13DFiling Source: edgar
    Filing Date: April, 30 2018
    Notification that form 20-F will be submitted late
    Filing Type: NT 20-FFiling Source: edgar
    Filing Date: April, 27 2018
    Amendment to a SC 13D filing
    Filing Type: SC 13D/AFiling Source: edgar
    Filing Date: April, 23 2018
    Amendment to a SC 13D filing
    Filing Type: SC 13D/AFiling Source: edgar
    Filing Date: April, 19 2018
    Amendment to a SC 13D filing
    Filing Type: SC 13D/AFiling Source: edgar
    Filing Date: April, 13 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 09 2018

     

     


    Daily Technical Chart for (NASDAQ: ARCT)

    Daily Technical Chart for (NASDAQ: ARCT)


    Stay tuned for daily updates and more on (NASDAQ: ARCT)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: ARCT)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    OTC Report
    @OTCReporter

     

     


    Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ARCT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of ARCT and does not buy, sell, or trade any shares of ARCT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/